Objective: The aim of this work was to assess baseline serum levels of established biomarkers 5 related to inflammation and oxidative stress in nearly 200 serum samples from AKU subjects 6 enrolled in SONIA1 and SONIA2 clinical trials (DevelopAKUre project). 7
Introduction

29
Alkaptonuria (AKU) is a rare autosomal recessive metabolic disorder (MIM 203500) causing an 30 early onset, chronically debilitating spondylo-arthropathy due to high circulating homogentisic acid 31 (HGA, 2,5-dihydroxyphenylacetic acid) [1] . Accumulation of HGA is due to mutations of the HGD 32 gene causing the production of a defective HGD enzyme in tyrosine and phenilalanine catabolic 33 pathways [2] . Excess HGA is partly eliminated in the urine, partly contributes to the production of 34 an ochronotic pigment deposited in cartilagineous tissues, which leads to a range of clinical 35 manifestations. AKU causes considerable morbidity in adulthood, and cases of acute fatal 36 metabolic complications (oxidative haemolysis and/or methaemoglobinaemia) were reported [3] . 37
So far, no correlation between genotype and HGA circulating levels has been found. 38 AKU still lacks appropriate biomarkers to monitor progression excepting for an AKU Severity Score 39 Index (AKUSSI) [4] . The use of nitisinone (NTBC) was suggested in AKU to lower circulating HGA 40 levels, and clinical trials were undertaken in Europe (DevelopAKUre -Clinical Development of 41
Nitisinone for Alkaptonuria) [5] . Recent evidence pointed out also that AKU is a multisystem 42 disease involving secondary (AA) amyloidosis due to high circulating Serum Amyloid A (SAA) 43 promoting inflammation, oxidative stress and amyloidosis [6, 7] . The presence of SAA and Serum 44
Amyloid P (SAP) in in vitro and ex vivo AKU models highlighted the amyloid nature of ochronotic 45 pigment [6, 8, 9] . So far, AA amyloid has been reported in AKU in several tissues: 46 a. cartilage [9-11] 47 7 obtained for each analysed dataset. Mann-Whitney, Kruskal-Wallis followed by Dunn's multiple 151 comparisons, and Spearman's rank correlation analysis were used as appropriate. 152 153
Results
154
The overall aim of this work was to assess baseline levels of established biomarkers related to 155 inflammation and oxidative stress in serum from alkaptonuric patients who were/are enrolled in 156
DevelopAKUre clinical trials. The tested biomarkers included well-known mediators of inflammatory 157 responses (IL-6, IL-1β, TNFα and CRP) and SAA, which play also a role in inflammation, oxidative 158 stress, and secondary (AA) amyloidosis. Serum levels of the following biomarkers were also 159 tested: cathepsin D (CATD), a lysosomal aspartic protease taking part in intracellular digestion of 160 proteoglycan in the initial stages of osteoarticular inflammation [25] and involved in degradation of 161 SAA, preventing amyloid deposition [26] ; IL-1 receptor antagonist (IL-1ra), which is specific for 162 preventing the activity of IL-1α and IL-1β by competing with IL-1α and IL-1β for binding to the 163 ligand-binding chain, termed type I (IL-1RI); metalloproteinase 3 (MMP-3), which is involved in 164 extracellular matrix remodelling and whose serum levels are increased in inflammatory rheumatic 165 diseases [27] . 166 AOPP were tested as oxidative stress and potential inflammatory mediators, as they are found in 167 several human diseases where these events are involved, such as chronic renal failure and [21, 168 28], diabetes mellitus [29] , obesity and insulin resistance [30] and their pro-inflammatory activity 169 was demonstrated [31] . Free serum protein thiols (PSH), S-thiolated proteins, and PTI were 170 measured to assess oxidative stress. 171
SONIA1
8 hematological parameters such as: glucose, cystatin C, alkaline phosphatase (data not shown), 178 cholesterol, tryglicerides and LDL-cholesterol (Table 3S) were generally in range, whereas HDL-179 cholesterol scored below the reference range in 90% of the tested AKU subjects (Table 3S) . 180
[suggested position for Table 1 ] 181
The possible dependence of the tested inflammatory biomarkers from age, BMI, smoking and 182 drinking habits, gender and site of sample collection was evaluated. No differences according to 183 gender or cigarette smoking habits could be highlighted ( Table 2) . As for the other confounding 184 factors, we found that CATD serum levels were significantly increased in subjects drinking alcohol 185 (P<0.0001) and that IL-1ra, TNFα and CRP serum levels were higher in overweight/obese subjects 186 compared to those with a normal BMI ( Table 2) . Interestingly, there were also some biomarkers 187 that showed a different distribution according to the clinical site: CATD (P<0.0001), IL-1β 188 (P=0.005) and MMP-3, (P<0.0001). Since AKU patients enrolled in Liverpool were from different 189
European nations, a common trait in different lifestyle or eating habits explaining such a difference 190
could not be identified yet [33] . Due to the chronic and progressive nature of AKU, several AKU 191 patients enrolled in SONIA1 presented with concomitant pathologies and/or reported the use of 192 concomitant medications. The possible effect of such concomitant medications on the levels of the 193 tested biomarkers was ruled out ( Figure 1S) . A positive and significant correlation was found for 194 SAA and CRP (Table 3) , and several inflammatory biomarkers were positively correlated to BMI 195 (SAA, IL-6, IL-1ra, TNFα and CRP). Conversely, none of the tested biomarkers was correlated to 196 serum HGA levels ( Table 3) . 197
[suggested position for Table 2 and Table 3 ] 198
SONIA2 199
SAA was the only marker, among those tested in SONIA1, that was measured also in SONIA2. 200
Chitotriosidase activity was included as an additional marker of non-infectious inflammation [34] . 201
Since increased AOPP [13] and PTI [15] were reported previoulsy in smaller cohorts of AKU 202 patients, AOPP, thiols, S-thiolated proteins and PTI were investigated in SONIA2. 203 AOPP ranged between 1.60-60.12 µmol/dL chloramine T equivalents (mean 12.45 ± 8.57 µmol/dL) 204 and were above the reference value (set at 30 µmol/dL) in six out of the 138 analysed samples9 (4%) ( Figure 1A) . No differences were found once AOPP were stratified according to subjects' age 206 SAA ranged between 1.5-311.9 mg/L (mean value 57.01 ± 64.80 mg/L). Interestingly, SAA serum 210 levels ranged between 3 and 10 mg/L in 18 subjects (13%) and were above the threshold of 10 211 mg/L [32] in 119 out of the 138 analysed samples (86%) (Figure 2A) . SAA levels showed no 212 differences once stratified according to subjects' age ( Figure 2B ), or sex ( Figure 2D) , whereas a 213 small but significant difference between underweight and obese AKU subjects was found. 214
Nevertheless, similar ranges were observed for SAA in normal (3.8-311.9 mg/L), overweight (1.5-215 305.7 mg/L) and obese (9.0-298.6 mg/L) AKU sujects ( Figure 2E ). SAA serum levels were also 216 positively and significantly correlated to subjects' BMI (r=0.3556, P<0.0001) ( Figure 2F ) but not 217 age (r=0.1268, P=0.1382) ( Figure 2C) . 218
[suggested position for Figure 2 ] 219 Chitotriosidase activity ranged between 8.2-187 nmoL/mL/h (mean value 60.32 ± 33.87 220 nmoL/mL/h) and was above the reference value (set at 51 nmoL/mL/h) in 72 out of the 138 tested 221 samples (52%) ( Figure 3A) . Increasing chitotriosidase activity was observed stratifying patients 222 according to their age ( Figure 3B ) and a positive correlation was found with age ( Figure 3C) . 223
Conversely, no differences were observed according to sex (Figure 3D ) or BMI classification 224 ( Figure 3E) , and no correlation was found with BMI ( Figure 3F) . 225
[suggested position for Figure 3 ] 226 Levels of free thiols and S-thiolated proteins, ultimately combined into PTI, did not differ 227 significantly beween control and AKU subjects ( Figure 2S ). However, a positive and significant 228 correlation was found bewteen PTI and AKU subjects' age [ Figure 4 When inflammatory and oxidative marker levels were correlated to the outcomes of health 236 questionnaires, we found weak but statistically significant correlations indicating that high levels of 237 SAA were more frequently associated both to a higher degree of difficulties in sport activities as 238 well as to a reduced perceived knee-related quality of life (KOOS questionnaire). Similarly, patients 239 with high PTI and chitotriosidase activity reported more frequently an increased severity of pain 240 and symptoms, difficulties in daily activities and sport, and a reduced perceived knee-related 241 quality of life (KOOS questionnaire) ( Table 4 ). We also found that high serum levels of SAA, PTI 242 and chitotriosidase activity were more frequently associated to an increased perception of disability 243 (haqDI, HAQ questionnaire) and to a reduced perceived physical health (i.e., lower levels of 244 functioning according to SF-36) ( [35, 36] . Though AKU represents the iconic prototype "inborn 253 error of metabolism" and shares features with other more common rheumatic diseases, it still lacks 254 appropriate biomarkers to monitor severity and progression. Hence, this work was undertaken with 255 the main aim of analysing levels of established biomarkers related to oxidative stress and 256 inflammation in a large cohort of alkaptonuric patients. Due to the ultra-rarity of the disease 257 (affecting 1:250,000-1,000,000 [1]), we were given an invaluable opportunity, as we were able to 258 test for the very first time a high number of alkaptonuric serum specimens that were collected and 259 stored under standardised procedures (agreed among the involved clinical centres). Our analyses 11 Confirming previous evidence from ours [6] [7] [8] [9] 37] , the major finding of this study was that SAA 262 seemed the most promising biomarker to be assessed in AKU to monitor inflammation. SAA serum 263 levels were significantly increased compared to reference threshold in the vast majority of samples. 264 A similar trend was observed for another inflammatory biomarker, namely chitotriosidase, whose 265 activity was above the reference range in half of the tested samples. These findings suggest that 266 sub-clinical inflammation may be relevant in AKU and connected with the development of disease-267 related complications, similarly to other rheumatic conditions where increased SAA levels can be 268 found, such as: osteoarthritis (OA Conversely, serum AKU-related oxidative stress markers that were shown to be increased in 271 smaller cohorts of AKU subjects such as AOPP [13] and PTI [15] , in this work were not significantly 272 different from a control population. 273
Since CRP levels were increased only in a minority of the tested AKU subjects, superiority of SAA 274
and chitotriosidase compared to CRP to monitor subclinical inflammation might be suggested in 275 AKU. This is similar to what observed for SAA in patients suffering from FMF [44, 47, 48] and is 276 further supported by recent works where SAA was proposed as a better biomarker than CRP to 277 monitor rheumatic disease activity [41, 46, 49, 50] or response to pharmacological treatment [43, 278 44, 51] . 279
Additionally, since plasma SAA levels correlate with SAA levels in synovial fluid, passive diffusion 280 of SAA from systemic circulation to synovial joint may be speculated [38] . This is particularly 281 relevant due to the role that SAA might play in joint destruction through induction of 282 metalloproteinases and collagen [41] although different functions have been suggested for 283 systemic and locally-produced SAA isoforms, as well as for acute and constitutive SAA [41] . SAA 284 may thus be considered a mediator of "danger signal" driving inflammatory processes in AKU. 285
The serum concentration of SAA closely reflects the activity and severity of OA [38] [54, 55] . We 287 provided evidence that AKU patients presenting with significantly higher SAA and chitotriosidase 288 activity (enhanced inflammation) and higher PTI (enhanced oxidative stress) reported more often a 289 decreased quality of life (as assessed through patients' health questionnaires) and scored higher in 290 the AKUSSI scale for joint and spinal pain. This suggests that worsening of symptoms in AKU is 291 paralleled by increased inflammation and oxidative stress, which might play a role in AKU 292 progression. Consequently, SAA, chitotriosidase activity and PTI might be proposed as disease 293 activity markers in AKU, although further evidence is needed. 294
The positive association between SAA and BMI that we found in the tested AKU subjects is not 295 new [41, [56] [57] [58] and might be justified by the fact that SAA is expressed both in liver and adipose 296 tissue [56] . In particular, in obesity (where low-grade inflammation is found), adipose tissue is the 297 major source of SAA, which can be considered an obesity-related inflammatory protein [57, 59] . It 298 is known that HDL counter-regulates SAA and other pro-inflammatory mediators [60] . Interestingly, 299
we found that 90% of the tested AKU subjects enrolled in SONIA1 had lower levels of HDL than 300 what established by reference guidelines. Chronic inflammation, as outlined in FMF, RA and SLE 301 subjects [48, [61] [62] [63] might alter the structure and functions of HDL, overall impairing HDL 302
properties. In particular, a decreased antioxidant activity of HDL might follow displacement of 303 ApoA-I from HDL due to high SAA. Since altered profiles in apolipoproteins were documented by 304 comparative proteomics of AKU serum [13] , this topic deserves further investigations in AKU. 305
306
Reactive systemic AA amyloidosis can complicate chronic inflammatory disorders that are 307 associated with a sustained acute phase response. AA amyloid fibrils are derived from the acute-308 phase reactant SAA through a process of cleavage, misfolding, and aggregation into a highly 309 ordered abnormal β-sheet conformation (amyloid) [32] . Sustained overproduction of SAA is a 310 prerequisite for the development of AA amyloidosis [32] . 311
Persistently elevated SAA levels represent a risk factor for the development of amyloidosis due to 312 deposition of amyloid aggregates in several organs and tissues. However, physiological and 313 pathological functions of SAA are still partly unclear and differences between recombinant and 314 endogenous SAA have been highlighted in in vitro assays, probably due to a difference in 315 association to lipids [41, 59] . Pathological SAA serum levels were found to fall within a wide range 316 in the tested AKU subjects. This finding becomes particularly relevant in the light of a very recent13 work [64] where HGA was found to act as an amyloid aggregation enhancer in vitro (in a time-and 318 dose-dependent fashion) for amyloidogenic proteins and peptides, such as: Aβ(1-42), 319 transthyretin, atrial natriuretic peptide, α-synuclein and SAA. In particular, the pro-aggregating 320 effect of HGA towards SAA was found even at nearly physiological HGA concentrations [64] . Thus, 321 based on the results presented in this work, pharmacological control of SAA circulating levels in 322 AKU seems appropriate to be suggested. 323
324
We believe our study presents a number of strengths. Considering the rarity of the disease, the 325 number of tested samples (nearly 200) and biomarkers is noteworthy. Furthermore, homogenous 326 study samples were collected thanks to tight coordination between the involved clinical sites. 327
Lastly, this was the first time that inflammatory and oxidative stress biomarkers could be 328 investigated in vivo in AKU. Conversely, since AKU is not life-threating, the presence of 329 concomitant pathologies or medications has to be taken into account due to the 330 chronic/progressive nature of the disease. In this respect, it should be underlined that all the 331 possible confounding factors collected during the studies (smoking, drinking, concomitant use of 332 drugs) were considered in our analysis. All the data obtained within this work could hence be used 333 to populate a dedicated database integrating biomarker levels, demographics, patient's quality of 334 life, environmental and life-style data, and clinical outcomes. Such a database could represent an 335 optimal tool with potential relapses for the study of AKU and the development of a precision 336 medicine approach for AKU and other more common rheumatic disorders [65] . 337
338
In the light of data presented here showing increased serum SAA in AKU, an appropriate 339 pharmacological treatment able to address this feature of the disease could be suggested as well. 340
Low dose methotrexate (MTX) can down-regulate inflammation acting on several steps triggering 341 and perpetuating inflammation [66] . In particulat, thanks to its ability to lower SAA production, MTX 342 at low dosages is the anchor drug to treat rheumatic diseases and the associated AA amyloidosis 343 [32, 67, 68] . Control of the acute phase response is currently the standard of care in amyloidosis 344 and rheumatic disorders [32, 69] Table 4 Supplemental Material Click here to download Supplemental Material: SUPPLEMENTARY MATERIAL SANTUCCI O&C 2017.docx
